MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) will report third-quarter 2026 financial results and provide a business update November 4, giving investors an opportunity to assess the Malvern-based biotechnology company’s progress in developing gene therapies for inherited retinal diseases and other causes of blindness.
The company said it will host a conference call and webcast at 8:30 a.m. Eastern Time, with financial materials available on its investor website before the presentation.
Ocugen is developing a modifier gene therapy platform designed to address retinal diseases through a gene-agnostic approach, rather than targeting individual genetic mutations.
The technology is intended to restore balance across multiple gene networks associated with disease progression, potentially allowing treatments to address broader patient populations than therapies developed for specific mutations.
The company’s development programs target retinitis pigmentosa, Stargardt disease and geographic atrophy, an advanced form of dry age-related macular degeneration.
These conditions can cause progressive vision loss and represent areas of unmet medical need.
Ocugen’s November 4 update will cover its financial performance and business activities as it advances its ophthalmic gene therapy programs.
Investors can access the live webcast at https://edge.media-server.com/mmc/p/w8rytgud.
Telephone participants can join by calling 800-715-9871 in the United States or 646-307-1963 internationally, using access code 6835403.
A replay of the conference call and an archived webcast will be available through Ocugen’s investor website.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.